An essential overview of the biological role of coronavirus viroporin (envelope protein) is given, together with the effect of its known inhibitors on the life cycle of coronavirus A docking study is conducted using a set of known drugs approved worldwide (ca 6000 compounds) on a structure of the SARS-CoV-2 viroporin modelled from the published NMR-resolved structures The screening has identified 36 promising drugs currently on the market, which could be proposed for pre-clinical trials
Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs